Optimizing Obesity Management With GLP‐1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review
Obesity Science & Practice · 2026-04 · 12 (2)
DOI: 10.1002/osp4.70140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity Science & Practice, online erschienen am 04.04.2026. Verfasst von Elizabeth Sharp Edens und 3 weiteren Autor:innen. Beteiligte Einrichtung: TouchCare Method, Health Meets Wellness, Bucks Health and Wellness New York New York USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
GLP‐1 RAs are effective in treating obesity; however, they typically result in significant loss of skeletal muscle mass. Real‐world evidence to inform systematic guidelines and clinical implementation for preserving skeletal muscle mass and reducing cardiometabolic risk with lifestyle modifications on GLP‐1 RAs remains limited.
Objective
This study evaluated the effectiveness of the TouchCare Method, a lifestyle intervention incorporating nutrition and exercise with GLP‐1 RAs, for improving body composition and cardiometabolic risk.
Methods
A retrospective chart review included patients enrolled in Bucks Health and Wellness between February 2024 and September 2025, for at least 12 month ( n = 187). The TouchCare Method incorporates registered dietitian counseling, progressive exercise programming, mobile self monitoring, and body composition analysis during visits. Primary outcomes included: clinically significant weight loss (> 10% of body weight), proportion of weight loss from skeletal muscle mass, and changes in total‐C, LDL‐C, Apolipoprotein B, Triglycerides, HbA1c, and blood pressure at 12 months.
Results
Patients adherent to the TouchCare Method for 12 months were included in the final analysis ( n = 171). Clinically significant weight loss (≥ 10%) was achieved by 69.56% ( n = 139) of patients. Skeletal muscle mass accounted for 12.22% ± 8.73% of total weight loss. Among prediabetic patients ( n = 95), 74.7% ( n = 71) reached euglycemia by 12 months. Patients with Stage II hypertension or higher (77% of the cohort) demonstrated improved blood pressure control, with most reaching < 140/90 mmHg. Patients with HLD experienced significant reductions in Total‐C (24.71 ± 23.31 mg/dL), LDL‐C (−13.75 ± 21.51 mg/dL), and ApoB (−14.24 ± 16.19 mg/dL). All lipid and HgA1c changes were statistically significant ( p < 0.001).
Conclusion
The TouchCare Method may improve GLP‐1 RA treatment outcomes by providing comprehensive structured lifestyle interventions supporting clinically significant weight loss while preserving skeletal muscle mass and improving cardiometabolic risk factors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- TouchCare Method, Health Meets Wellness, Bucks Health and Wellness New York New York USA.
ORCID-Profile: Elizabeth Sharp Edens
Zitieren
APA
Edens, E. S., Falise, H., Smith, R., & Bernardo, E. (2026). Optimizing Obesity Management With GLP‐1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review. Obesity Science & Practice, 12(2). https://doi.org/10.1002/osp4.70140
Vancouver
Edens ES, Falise H, Smith R, Bernardo E. Optimizing Obesity Management With GLP‐1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review. Obesity Science & Practice. 2026;12(2). doi:10.1002/osp4.70140
BibTeX
@article{Edens2026,
author = {Edens, Elizabeth Sharp and Falise, Heather and Smith, Rebecca and Bernardo, Elle},
title = {Optimizing Obesity Management With GLP‐1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review},
journal = {Obesity Science & Practice},
year = {2026},
volume = {12},
number = {2},
doi = {10.1002/osp4.70140}
}
EUVIMED